



Publication of the 2009 Annual Financial Report

Paris, April 6, 2010 – BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today that its 2009 Annual Financial Report has been sent to the French Market Authorities and may be consulted at the <http://www.bioalliancepharma.com> website,

<http://www.bioalliancepharma.com/eng/Investisseurs/Information-reglementee-AMF>

The Annual Financial Report comprises the report by the Chairman of the Supervisory Board on the Board's activities and on internal controls, the statutory Auditors' fees, and the annual information document.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

BioAlliance Pharma SA

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com